Andras A. Heczey, MD
Department or Service
- Texas Medical Center
Director, Liver Tumor Program
Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
|Semmelweis University||medical school||Doctor of Medicine||2002|
|Baylor College of Medicine||fellowship||Pediatric Hematology Oncology||2012|
|Children's Hospital of Los Angeles||residency||Pediatrics||2009|
|Semmelweis Medical University, Hungary||residency||Infectious Disease||2006|
Dr. Andras Heczey is a physician-scientist and full-time faculty in the Department of Pediatrics of Baylor College of Medicine, Section of Pediatric Hematology and Oncology. He is a member of the multidisciplinary solid tumor team and the Center for Cell and Gene Therapy (CAGT).
General Pediatrics, American Board of Pediatrics
Pediatric Hematology and Oncology, American Board of Pediatrics
|American Society of Cell and Gene Therapy||Member|
|American Society of Clinical Oncology (ASCO)||Member|
|American Society of Pediatric Hematology and Oncology (ASPHO)||Member|
|Children's Oncology Group (COG)||Member|
His research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack cancer cells.
Dr. Heczey has studied and published the first adoptive immunotherapy approach utilizing Natural Killer T cells genetically modified to attack neuroblastoma, he is working on moving this approach from bench-to-bedside in a form of a Phase 1/2a clinical trial.
As the Director of the Liver Tumor Center, Dr. Heczey has developed a strategy to target hepatoblastoma and hepatocellular carcinoma with genetically engineered T lymphocytes and he is currently optimizing this strategy for a smooth transition into the clinic.
Dr. Heczey’s research is focused on redirecting the immune system to attack and kill cancer cells by using genetically engineered T cells and Natural Killer T cells. He has developed bispecific T cell engagers and chimeric antigen receptors, which when expressed in T cells, specifically target hepatoblastoma and hepatocellular carcinoma. His goal is to cure all patients with liver cancers by translating these methods from the laboratory setting to the patient care clinic.
Good Student and Good Athlete of the Republic of Hungary, 2000. From the Ministry of Education of Hungary
Associates and Affiliates Award of the Children's Hospital of Los Angeles, 2009, For scientific knowledge, clinical judgment and excellence in human relations
Tumor Board Award, 2010, Texas Children's Cancer and Hematology Centers
Chief Fellow, 2011-2012, Texas Children's Cancer and Hematology Centers
Fellows’ Excellence in Education Award, 2015, Texas Children's Cancer and Hematology Centers
Faculty Recognition Award, 2017, Texas Children’s Cancer and Hematology Centers
Biotherapeutics Award, 2017, Alex's Lemonade Stand Foundation